Clinical trials: Alzheimer Disease (AD)
Alzheimer's Disease
Effect of REST in the Alzheimer Disease Continuum
The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus.
- Trial name
- ERADC (NCT03884023)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Dongzhimen Hospital, Beijing
Healthy Aging, Alzheimer's Disease (AD)
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
Developing efficient cognitive intervention for cognitively health older adults is a major public health goal, due to its potential for reducing age-related cognitive decline and Alzheimer's disease/dementia risk.
- Trial name
- MUST (NCT06995638)
- Testing
- Web-based Cognitive Training (with strategy), Web-based Cognitive Training (without strategy)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Alzheimer Disease
Correlation of P-glycoprotein Polymorphisms With Microbial Metabolites in Patients With Alzheimer's Disease on Medication
The importance of the proposed study concerns the understanding of the way in which each drug acts in each organism separately, both at the genome level and at the microbiome level.
- Trial name
- NCT05532644
- Testing
- AD drugs
- Where
- Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Inactivity, Physical
BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD
This 12-week trial will test the efficacy of a multi-component, personalized text-message delivered behavior change technique (BCT) intervention to encourage habitual physical activity (defined as regular walking of 1,000 or more…
- Trial name
- NCT06803797
- Testing
- Behavior Change Technique Package
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Social Isolation, SCD
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1.
- Conditions
- Social Isolation, SCD, Subjective Cognitive Decline, MCI
- Trial name
- NCT06335836
- Testing
- social isolation
- Where
- China
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord.
- Trial name
- SHARP (NCT00939822)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy Volunteers, Tauopathies
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo.
- Conditions
- Healthy Volunteers, Tauopathies, Alzheimer Disease
- Trial name
- NCT05344989
- Testing
- APNmAb005
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer's Disease (AD)
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.
- Trial name
- NCT03802162
- Testing
- CKD-355A (D797/Memantine HCl 20mg), CKD-355B (D797/Memantine HCl 20mg), D797
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Alzheimer Disease
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD.
- Trial name
- NCT03720548
- Testing
- LY3372993
- Where
- 11 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of the Effectiveness and Safety of Transcranial Direct Current Stimulation in Combination With Nasal Near Infrared Stimulation to Improve Cognitive Functions and Quality of Life in Elderly People With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD).
Alzheimer's disease (AD) and mild cognitive impairment (MCI) are progressive neurodegenerative conditions with limited therapeutic options. Today, around 30 million people worldwide suffer from Alzheimer's dementia.
- Trial name
- NCT07290686
- Testing
- tDCS stimulation, tDCS, iNIRS stimulation
- Where
- Poland
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Mild Cognitive Impairment (MCI), Dementia
An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers.
- Trial name
- NCT07127133
- Testing
- Insole and ankle device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Alzheimer Disease, Healthy Volunteers
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
- Trial name
- NCT03071224
- Testing
- [18F] MNI-946, [18F]Florbetapir
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer Disease
HAPPCAP-AD (Human-APPlication Combined Approach for Prevention of Alzheimer's Disease)
Currently, Alzheimer's disease (AD) has no cure putting prevention-strategies in the forefront for impeding the public health and personal consequences of this devastating disease.
- Trial name
- HAPPCAP-AD (NCT05256121)
- Testing
- AD Risk factors balance
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug…
- Trial name
- NCT01795339
- Testing
- AZD3293
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer Disease, Benson's Disease
Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)
Recently revised Alzheimer Disease (AD) diagnostic1described nonamnestic presentations: 1/ language presentation (logopenic progressive aphasia) 2/ visuospatial presentation (posterior cortical atrophy or PCA) and 3/ executive…
- Trial name
- TEPTAU (NCT03022968)
- Testing
- [18F]T807 PET
- Where
- France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Healthy, Subjective Cognitive Decline (SCD)
Sleep Stimulation to Enhance Waste Clearance in the Brain
This study aims to examine whether multi-night closed-loop auditory stimulation (CLAS) during sleep can enhance waste clearance and memory consolidation in healthy adults and older adults with subjective cognitive decline or mild…
- Conditions
- Healthy, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
- Trial name
- NCT07051239
- Testing
- Closed-loop acoustic stimulation
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital